SAN DIEGO--(BUSINESS WIRE)-- TRIO Pharmaceuticals, Inc., a biotechnology company pioneering bispecific antibodies for the treatment of cancer with unprecedented potency and selectivity, announced the successful completion of a $3.1 million financing round. TRIO’s pre-Series A financing was led by San Diego based Friedman Bioventure Fund (FBVF). “The TRIO team has demonstrated impressive bioactivity for both their TRAILBody and TIE-ADC bispecific antibody architectures, and we believe these potential medicines warrant accelerated development,” said Dr. Jeff Friedman of FBVF.